Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 47

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 47
---
 commercial registry of the Canton of Zurich, Switzerland, on September 18, 2024. The reverse split became effective in Switzerland on September 18, 2024. The reverse stock split was at a ratio of 1 -for-40. In addition, on September 29, 2025, the NLS’s shareholders approved a further reverse stock split at a ratio of 1 -for-10, or the 2025 RSS. The accompanying unaudited pro forma condensed combined financial information does not give effect to the 2025 RSS, as certain procedural and regulatory steps required under Swiss corporate law remain outstanding before the split can be effectuated and become effective for accounting and reporting purposes. 5. Estimated Purchase Price Consideration On November 4, 2024, NLS, Kadimastem and Merger Sub entered into the Merger Agreement, pursuant to which, Merger Sub will merge with and into Kadimastem, with Kadimastem surviving as a wholly -ownedsubsidiary of NLS. Pursuant to the Merger Agreement, the Kadimastem shareholders agreed to convert their share capital in exchange for the right to receive a number of validly issued, fully paid and nonassessable NLS Common Shares, equal to the Exchange Ratio, per each such Kadimastem Ordinary Share. The following is a summary of the components of the estimated consideration in equity if the acquisition of Kadimastem had occurred on October 3, 2025:

| Estimated outstanding NLS Common Shares and NLS Common Shares underlying outstanding NLS Preferred Shares, options and warrants*                      |     |  9,320,386 |   |
| Estimated Kadimastem Shares at time of the Merger (assuming exercise of all Common Warrants into NLS Common Shares)*                                  |     |  7,295,376 |   |
| Elimination of Kadimastem Ordinary Shares                                                                                                             |     | (7,295,376 | ) |
| Issuance of NLS Common Shares to Kadimastem shareholders including convertible loans, RSUs and options                                                |     | 50,423,799 |   |
| Total NLS Common Shares and NLS Common Shares underlying outstanding Preferred Shares and Preferred Participation Certificates outstanding at Closing |     | 56,538,856 |   |
| Exchange Ratio:                                                                                                                                       |     |     6.9117 |   |

____________ *Represents NLS’s outstanding shares as of October